MedTrace Logo

A Study Of PF-04449913 In Select Hematologic Malignancies

NCT00953758 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 47

Last updated 2024-04-25

Study results available
· View outcomes & findings →

Summary

This study examines the effect of a small molecule inhibitor to the Sonic Hedgehog pathway on select hematologic malignancies.

Conditions

Interventions

DRUG

PF-04449913

Escalating doses of PF-04449913 administered as tablets PO QD continuously in 28 day cycles

Sponsors & Collaborators

Principal Investigators

  • Pfizer CT.gov Call Center · Pfizer

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-03-03
Primary Completion
2012-09-26
Completion
2013-02-27

Countries

  • United States
  • Italy

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00953758 on ClinicalTrials.gov